+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer



Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer



Journal of Oncology 2014: 312193



Objective. The aim of this study was to document the survival advantage of lowering stage at detection from Stage IIIC to Stage IIIA epithelial ovarian cancer. Methods. Treatment outcomes and survival were evaluated in patients with Stage IIIA and Stage IIIC epithelial ovarian cancer treated from 2000 to 2009 at the University of Kentucky Markey Cancer Center (UKMCC) and SEER institutions. Results. Cytoreduction to no visible disease (P < 0.0001) and complete response to platinum-based chemotherapy (P < 0.025) occurred more frequently in Stage IIIA than in Stage IIIC cases. Time to progression was shorter in patients with Stage IIIC ovarian cancer (17 ± 1 months) than in those with Stage II1A disease (36 ± 8 months). Five-year overall survival (OS) improved from 41% in Stage IIIC patients to 60% in Stage IIIA patients treated at UKMCC and from 37% to 56% in patients treated at SEER institutions for a survival advantage of 19% in both data sets. 53% of Stage IIIA and 14% of Stage IIIC patients had NED at last followup. Conclusions. Decreasing stage at detection from Stage IIIC to stage IIIA epithelial ovarian cancer is associated with a 5-year survival advantage of nearly 20% in patients treated by surgical tumor cytoreduction and platinum-based chemotherapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056042560

Download citation: RISBibTeXText

PMID: 25254047

DOI: 10.1155/2014/312193


Related references

Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. Journal of Gynecologic Oncology 19(4): 223-228, 2008

Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstetricia et Gynecologica Scandinavica 98(1): 34-43, 2019

Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B. Gynecologic Oncology 107(1): 154-156, 2007

The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. International Journal of Gynecological Cancer 14(1): 51-56, 2004

Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi 30(4): 298-301, 2008

Long-Term Survival and Cost of Treatment in Patients with Stage IIIC Epithelial Ovarian Cancer. Current Women's Health Reviews 5(1): 44-50, 2009

Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only. European Journal of Gynaecological Oncology 33(6): 615-616, 2012

Survival impact of complete cytoreductive surgery in the primary management of FIGO stage IIIC, high-grade, epithelial ovarian cancer. Journal of Clinical Oncology 26(15_Suppl): 16551-16551, 2016

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. Journal of Gynecologic Oncology 28(4): E48, 2017

Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecologic Oncology. 46(3): 357-360, 1992

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of Surgical Oncology 107(2): 195-200, 2013

Response 2nd look status and survival in stage iii and stage iv epithelial ovarian cancer treated with cis di chloro di ammine platinum ii adriamycin and cytoxan. Gynecologic Oncology 10(3): 367-368, 1980

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. International Journal of Gynecological Cancer 22(8): 1337-1343, 2012

Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival. European Journal of Gynaecological Oncology 37(3): 305-311, 2016

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer. Gynecologic Oncology Reports 20: 131, 2017